{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06465069",
            "orgStudyIdInfo": {
                "id": "LOXO-LNC-24001"
            },
            "secondaryIdInfos": [
                {
                    "id": "J5I-OX-JZYA",
                    "type": "OTHER",
                    "domain": "Eli Lilly and Company"
                },
                {
                    "id": "2024-512927-36-00",
                    "type": "CTIS"
                }
            ],
            "organization": {
                "fullName": "Eli Lilly and Company",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors",
            "officialTitle": "A Phase 1a/1b Study of LY4052031, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants With Advanced or Metastatic Urothelial Carcinoma or Other Solid Tumors",
            "acronym": "NEXUS-01",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "a-study-of-in-participants-with-advanced-or-metastatic-urothelial-cancer-or-other-solid-tumors"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-07-01",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2027-05",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-05",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-06-13",
            "studyFirstSubmitQcDate": "2024-06-13",
            "studyFirstPostDateStruct": {
                "date": "2024-06-18",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-24",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-25",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Eli Lilly and Company",
                "class": "INDUSTRY"
            },
            "collaborators": [
                {
                    "name": "Loxo Oncology, Inc.",
                    "class": "INDUSTRY"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.",
            "detailedDescription": "This is a Phase 1a/1b multicenter, open-label study in participants with advanced or metastatic solid tumor malignancies known to express Nectin 4. This study is comprised of two phases: Dose Escalation and Dose Optimization (1a), and Dose expansion (1b). Phase 1a will assess the safety, tolerability, and pharmacokinetics of LY4052031 to determine the recommended phase 2 dose (RP2D)/optimal dose. Phase 1b will evaluate efficacy and safety of LY4052031 at the RP2D/optimal dose in expansion cohorts based on tumor type and/or treatment history."
        },
        "conditionsModule": {
            "conditions": [
                "Metastatic Solid Tumor",
                "Recurrent Solid Tumor",
                "Advanced Solid Tumor",
                "Urinary Bladder Neoplasm",
                "Triple Negative Breast Cancer",
                "Non-small Cell Lung Cancer",
                "Esophageal Cancer",
                "Pancreatic Cancer",
                "Ovarian Cancer",
                "Cervical Cancer",
                "Head and Neck Squamous Cell Carcinoma",
                "Prostate Cancer",
                "Renal Pelvis Cancer",
                "Bladder Cancer"
            ],
            "keywords": [
                "Bladder Cancer",
                "Bladder Neoplasm",
                "Bladder Urothelial Carcinoma",
                "Urinary Bladder Cancer",
                "Urinary Tract Cancer",
                "Urothelial Neoplasms",
                "Renal Pelvis Cancer",
                "Ureter Cancer",
                "Nectin-4",
                "Antibody Drug Conjugate (ADC)",
                "Triple Negative Breast Cancer (TNBC)",
                "Non-small Cell Lung Cancer (NSCLC)",
                "Head and Neck Squamous Cell Carcinoma (HNSCC)"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 220,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "LY4052031 (Dose-escalation, Cohort A1)",
                    "type": "EXPERIMENTAL",
                    "description": "Escalating doses of LY4052031 administered intravenously (IV).",
                    "interventionNames": [
                        "Drug: LY4052031"
                    ]
                },
                {
                    "label": "LY4052031 (Dose-optimization, Cohort A2)",
                    "type": "EXPERIMENTAL",
                    "description": "Comparing 2 or more doses (evaluated during dose escalation) of LY4052031 administered IV.",
                    "interventionNames": [
                        "Drug: LY4052031"
                    ]
                },
                {
                    "label": "LY4052031 (Dose-expansion, Cohort B1, B2, C1)",
                    "type": "EXPERIMENTAL",
                    "description": "LY4052031 administered IV.",
                    "interventionNames": [
                        "Drug: LY4052031"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "LY4052031",
                    "description": "Intravenous",
                    "armGroupLabels": [
                        "LY4052031 (Dose-escalation, Cohort A1)",
                        "LY4052031 (Dose-expansion, Cohort B1, B2, C1)",
                        "LY4052031 (Dose-optimization, Cohort A2)"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Phase 1a: To determine the recommended phase 2 dose (RP2D) or optimal dose of LY4052031",
                    "description": "Number of participants with dose-limiting toxicities (DLTs)",
                    "timeFrame": "Cycle 1 (21 Days)"
                },
                {
                    "measure": "Phase 1b: To assess the antitumor activity of LY4052031 Monotherapy: Overall response rate (ORR)",
                    "description": "ORR per investigator assessed Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1)",
                    "timeFrame": "Up to Approximately 48 Months or 4 Years]"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "To characterize the pharmacokinetics (PK) properties of LY4052031: Minimum Plasma Concentration (Cmin)",
                    "description": "PK: Cmin of LY4052031",
                    "timeFrame": "Cycle 1 (21 Days)"
                },
                {
                    "measure": "To characterize the PK properties of LY4052031: Area under the concentration versus time curve (AUC)",
                    "description": "PK: AUC of LY4052031",
                    "timeFrame": "Cycle 1 (21 Days)"
                },
                {
                    "measure": "To evaluate the preliminary antitumor activity of LY4052031: Overall response rate (ORR)",
                    "description": "ORR per investigator assessed Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1))",
                    "timeFrame": "Up to Approximately 48 Months or 4 Years"
                },
                {
                    "measure": "To evaluate the preliminary antitumor activity of LY4052031: Duration of response (DOR)",
                    "description": "DOR per investigator assessed RECIST 1.1",
                    "timeFrame": "Up to Approximately 48 Months or 4 Years"
                },
                {
                    "measure": "To evaluate the preliminary antitumor activity of LY4052031: Time to response (TTR)",
                    "description": "TTR per investigator assessed RECIST 1.1",
                    "timeFrame": "Up to Approximately 48 Months or 4 Years"
                },
                {
                    "measure": "To evaluate the preliminary antitumor activity of LY4052031: Progression free survival (PFS)",
                    "description": "PFS per investigator assessed RECIST 1.1",
                    "timeFrame": "Up to Approximately 48 Months or 4 Years"
                },
                {
                    "measure": "To evaluate the preliminary antitumor activity of LY4052031: Disease control rate (DCR)",
                    "description": "DCR per investigator assessed RECIST 1.1",
                    "timeFrame": "Up to Approximately 48 Months or 4 Years"
                },
                {
                    "measure": "To evaluate the preliminary antitumor activity of LY4052031: Overall survival (OS)",
                    "description": "OS per investigator assessed RECIST 1.1",
                    "timeFrame": "Up to Approximately 48 Months or 4 Years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Have one of the following solid tumor cancers:\n\n  * Cohort A1: urothelial carcinoma, triple negative breast cancer, non-small cell lung cancer, esophageal cancer, pancreatic cancer, ovarian cancer, cervical cancer (squamous cell carcinoma), head and neck squamous cell carcinoma or prostate cancer\n  * Cohort A2/B1/B2: urothelial carcinoma\n  * Cohort C: triple negative breast cancer, non-small cell lung cancer, ovarian cancer, cervical cancer, head and neck squamous cell carcinoma, esophageal cancer, pancreatic cancer, or prostate cancer\n* Prior Systemic Therapy Criteria:\n\n  * Cohort A1/C: Individual has received all standard therapies for which the participant was deemed to be an appropriate candidate by the treating investigator; OR there is no standard therapy available for the disease. There is no restriction on number of prior therapies\n  * Cohort A2/B1/B2: Individual must have received at least one prior regimen in the advanced or metastatic setting. There is no restriction on number of prior therapies.\n* Prior enfortumab vedotin specific requirements:\n\n  * Cohorts A1/A2/C: prior treatment with enfortumab vedotin is allowed, but not required\n  * Cohort B1: individual must be enfortumab vedotin naive in the advanced/metastatic setting\n  * Cohort B2: individual must have received enfortumab vedotin in the metastatic/advanced setting.\n* Measurability of disease\n\n  * Cohort A1: measurable or non-measurable disease as defined by Response Evaluation Criteria in Solid Tumors v1.1 (RECIST 1.1)\n  * Cohorts A2, B1, B2, C: measurable disease required as defined by RECIST v1.1\n* Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Have adequate archival tumor tissue sample available or undergo a screening biopsy if allowed per country specific regulations\n\nExclusion Criteria:\n\n* Individual with known or suspected uncontrolled CNS metastases\n* Individual with uncontrolled hypercalcemia\n* Individual with uncontrolled diabetes\n* Individual with evidence of corneal keratopathy or keratitis, and history of corneal transplant\n* Any serious unresolved toxicities from prior therapy\n* Significant cardiovascular disease\n* Recent thromboembolic event or bleeding disorder\n* Prolongation of QT interval corrected for heart rate using Fridericia's formula (QTcF) \u2265 470 ms\n* History of pneumonitis/interstitial lung disease\n* History of Grade \u22653 skin toxicity when receiving enfortumab vedotin\n* Individuals who are pregnant, breastfeeding or plan to breastfeed during study or within 30 days of last dose of study intervention",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or",
                    "role": "CONTACT",
                    "phone": "13176154559",
                    "email": "ClinicalTrials.gov@lilly.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Amy Eun Chang",
                    "affiliation": "Loxo Oncology, Inc.",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "START Midwest",
                    "status": "RECRUITING",
                    "city": "Grand Rapids",
                    "state": "Michigan",
                    "zip": "49546",
                    "country": "United States",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "phone": "855-569-6305"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.96336,
                        "lon": -85.66809
                    }
                },
                {
                    "facility": "South Texas Accelerated Research Therapeutics (START)",
                    "status": "RECRUITING",
                    "city": "San Antonio",
                    "state": "Texas",
                    "zip": "78229-3307",
                    "country": "United States",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "phone": "855-569-6305"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.42412,
                        "lon": -98.49363
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (NEXUS-01)",
                    "url": "https://trials.lilly.com/en-US/trial/503555"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000002277",
                    "term": "Carcinoma"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000002289",
                    "term": "Carcinoma, Non-Small-Cell Lung"
                },
                {
                    "id": "D000002294",
                    "term": "Carcinoma, Squamous Cell"
                },
                {
                    "id": "D000001749",
                    "term": "Urinary Bladder Neoplasms"
                },
                {
                    "id": "D000064726",
                    "term": "Triple Negative Breast Neoplasms"
                },
                {
                    "id": "D000077195",
                    "term": "Squamous Cell Carcinoma of Head and Neck"
                },
                {
                    "id": "D000010386",
                    "term": "Pelvic Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009375",
                    "term": "Neoplasms, Glandular and Epithelial"
                },
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000001943",
                    "term": "Breast Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000001941",
                    "term": "Breast Diseases"
                },
                {
                    "id": "D000012871",
                    "term": "Skin Diseases"
                },
                {
                    "id": "D000008175",
                    "term": "Lung Neoplasms"
                },
                {
                    "id": "D000012142",
                    "term": "Respiratory Tract Neoplasms"
                },
                {
                    "id": "D000013899",
                    "term": "Thoracic Neoplasms"
                },
                {
                    "id": "D000008171",
                    "term": "Lung Diseases"
                },
                {
                    "id": "D000012140",
                    "term": "Respiratory Tract Diseases"
                },
                {
                    "id": "D000014565",
                    "term": "Urogenital Neoplasms"
                },
                {
                    "id": "D000091642",
                    "term": "Urogenital Diseases"
                },
                {
                    "id": "D000052801",
                    "term": "Male Urogenital Diseases"
                },
                {
                    "id": "D000002283",
                    "term": "Carcinoma, Bronchogenic"
                },
                {
                    "id": "D000001984",
                    "term": "Bronchial Neoplasms"
                },
                {
                    "id": "D000018307",
                    "term": "Neoplasms, Squamous Cell"
                },
                {
                    "id": "D000052776",
                    "term": "Female Urogenital Diseases"
                },
                {
                    "id": "D000005261",
                    "term": "Female Urogenital Diseases and Pregnancy Complications"
                },
                {
                    "id": "D000014571",
                    "term": "Urologic Neoplasms"
                },
                {
                    "id": "D000001745",
                    "term": "Urinary Bladder Diseases"
                },
                {
                    "id": "D000014570",
                    "term": "Urologic Diseases"
                },
                {
                    "id": "D000006258",
                    "term": "Head and Neck Neoplasms"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5220",
                    "name": "Breast Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M5546",
                    "name": "Carcinoma, Non-Small-Cell Lung",
                    "asFound": "Non-small Cell Lung Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "asFound": "Carcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5030",
                    "name": "Urinary Bladder Neoplasms",
                    "asFound": "Urinary Bladder Neoplasms",
                    "relevance": "HIGH"
                },
                {
                    "id": "M14850",
                    "name": "Recurrence",
                    "relevance": "LOW"
                },
                {
                    "id": "M12974",
                    "name": "Ovarian Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M13110",
                    "name": "Pancreatic Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M14335",
                    "name": "Prostatic Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M5830",
                    "name": "Uterine Cervical Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M11172",
                    "name": "Lung Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M5550",
                    "name": "Carcinoma, Squamous Cell",
                    "asFound": "Squamous Cell Carcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5551",
                    "name": "Carcinoma, Transitional Cell",
                    "relevance": "LOW"
                },
                {
                    "id": "M8088",
                    "name": "Esophageal Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M30373",
                    "name": "Triple Negative Breast Neoplasms",
                    "asFound": "Triple Negative Breast Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1704",
                    "name": "Carcinoma, Ovarian Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M1689",
                    "name": "Squamous Cell Carcinoma of Head and Neck",
                    "asFound": "Head and Neck Squamous Cell Carcinoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M13297",
                    "name": "Pelvic Neoplasms",
                    "asFound": "Pelvis Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12320",
                    "name": "Neoplasms, Glandular and Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M5218",
                    "name": "Breast Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M15674",
                    "name": "Skin Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14979",
                    "name": "Respiratory Tract Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M16658",
                    "name": "Thoracic Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M11168",
                    "name": "Lung Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14977",
                    "name": "Respiratory Tract Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M17315",
                    "name": "Urogenital Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M2875",
                    "name": "Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27095",
                    "name": "Male Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M5540",
                    "name": "Carcinoma, Bronchogenic",
                    "relevance": "LOW"
                },
                {
                    "id": "M5260",
                    "name": "Bronchial Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M20451",
                    "name": "Neoplasms, Squamous Cell",
                    "relevance": "LOW"
                },
                {
                    "id": "M27093",
                    "name": "Female Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14127",
                    "name": "Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M8399",
                    "name": "Female Urogenital Diseases and Pregnancy Complications",
                    "relevance": "LOW"
                },
                {
                    "id": "M17320",
                    "name": "Urologic Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M5026",
                    "name": "Urinary Bladder Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M17319",
                    "name": "Urologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M9348",
                    "name": "Head and Neck Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "T4387",
                    "name": "Pancreatic Cancer",
                    "asFound": "Pancreatic Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "T4352",
                    "name": "Ovarian Cancer",
                    "asFound": "Ovarian Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "T5693",
                    "name": "Transitional Cell Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "T2141",
                    "name": "Esophageal Cancer",
                    "asFound": "Esophageal Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "T4354",
                    "name": "Ovarian Epithelial Cancer",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC08",
                    "name": "Respiratory Tract (Lung and Bronchial) Diseases"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "BC19",
                    "name": "Gland and Hormone Related Diseases"
                },
                {
                    "abbrev": "BC06",
                    "name": "Digestive System Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M4225",
                    "name": "Antibodies",
                    "relevance": "LOW"
                },
                {
                    "id": "M10184",
                    "name": "Immunoglobulins",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}